Drug intelligence / Profile preview

Ferro Zinc

Development stage: Unknown
Lead developer: Hacettepe University
Modality: Small Molecules
Administration: Oral

Overview

Ferro Zinc is an oral fixed-dose combination therapy containing iron and zinc, specifically evaluated by Hacettepe University for the treatment of iron deficiency anemia (IDA) in pediatric populations. The formulation is designed to replenish elemental iron stores to support hemoglobin synthesis while simultaneously addressing potential concurrent zinc deficiency, which often complicates IDA in children. The drug was the subject of a randomized, open-label clinical trial (NCT02076828) conducted at the Hacettepe University Faculty of Medicine, where its efficacy in restoring hematological parameters was compared against standard iron monotherapies such as ferrous sulfate (Ferro Sanol) and iron polymaltose complex (Santafer).

Brand names: Ferro Zinc
Other names: iron + zinciron-zinc combinationFerro Zinc sp.

Beyond the preview

Go deeper on Ferro Zinc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ferro Zinc.

Explore the full profile